Rapid, early, and potent Spike-directed IgG, IgM, and IgA distinguish asymptomatic from mildly symptomatic COVID-19 in Uganda, with IgG persisting for 28 months.

Saved in:

Bibliographic Details
Title:	Rapid, early, and potent Spike-directed IgG, IgM, and IgA distinguish asymptomatic from mildly symptomatic COVID-19 in Uganda, with IgG persisting for 28 months.
Authors:	Serwanga J; Pathogen Genomics, Phenotype, and Immunity Program, Medical Research Council, Uganda Virus Research Institute and London School of Hygiene and Tropical Medicine, Uganda Research Unit, Entebbe, Uganda.; Department of Immunology, Uganda Virus Research Institute, Entebbe, Uganda., Ankunda V; Department of Immunology, Uganda Virus Research Institute, Entebbe, Uganda., Sembera J; Department of Immunology, Uganda Virus Research Institute, Entebbe, Uganda., Kato L; Pathogen Genomics, Phenotype, and Immunity Program, Medical Research Council, Uganda Virus Research Institute and London School of Hygiene and Tropical Medicine, Uganda Research Unit, Entebbe, Uganda., Oluka GK; Pathogen Genomics, Phenotype, and Immunity Program, Medical Research Council, Uganda Virus Research Institute and London School of Hygiene and Tropical Medicine, Uganda Research Unit, Entebbe, Uganda.; Department of Immunology, Uganda Virus Research Institute, Entebbe, Uganda., Baine C; Department of Immunology, Uganda Virus Research Institute, Entebbe, Uganda., Odoch G; Pathogen Genomics, Phenotype, and Immunity Program, Medical Research Council, Uganda Virus Research Institute and London School of Hygiene and Tropical Medicine, Uganda Research Unit, Entebbe, Uganda., Kayiwa J; Department of Virology, Uganda Virus Research Institute, Entebbe, Uganda., Auma BO; Pathogen Genomics, Phenotype, and Immunity Program, Medical Research Council, Uganda Virus Research Institute and London School of Hygiene and Tropical Medicine, Uganda Research Unit, Entebbe, Uganda., Jjuuko M; Department of Internal Medicine, Masaka Regional Referral Hospital, Masaka, Uganda., Nsereko C; Department of Internal Medicine, Entebbe Regional Referral Hospital, Entebbe, Uganda., Cotten M; Pathogen Genomics, Phenotype, and Immunity Program, Medical Research Council, Uganda Virus Research Institute and London School of Hygiene and Tropical Medicine, Uganda Research Unit, Entebbe, Uganda.; Medical Research Council, University of Glasgow Centre for Virus Research, Glasgow, United Kingdom., Onyachi N; Department of Internal Medicine, Masaka Regional Referral Hospital, Masaka, Uganda., Muwanga M; Department of Internal Medicine, Entebbe Regional Referral Hospital, Entebbe, Uganda., Lutalo T; Department of Epidemiology and Data Management, Uganda Virus Research Institute, Entebbe, Uganda., Fox J; Guy's and St Thomas' National Health Services Foundation Trust, King's College London, London, United Kingdom., Musenero M; Science, Technology, and Innovation Secretariat, Office of the President, Government of Uganda, Kampala, Uganda., Kaleebu P; Pathogen Genomics, Phenotype, and Immunity Program, Medical Research Council, Uganda Virus Research Institute and London School of Hygiene and Tropical Medicine, Uganda Research Unit, Entebbe, Uganda.; Department of Immunology, Uganda Virus Research Institute, Entebbe, Uganda.
Corporate Authors:	COVID-19 Immunoprofiling Team
Source:	Frontiers in immunology [Front Immunol] 2023 Mar 16; Vol. 14, pp. 1152522. Date of Electronic Publication: 2023 Mar 16 (Print Publication: 2023).
Publication Type:	Journal Article; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural
Journal Info:	Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE
Database:	MEDLINE Ultimate

Description
ISSN:	1664-3224
DOI:	10.3389/fimmu.2023.1152522